James Mond Acquires 4,500 Shares of ADMA Biologics Inc (ADMA) Stock

ADMA Biologics Inc (NASDAQ:ADMA) EVP James Mond bought 4,500 shares of the company’s stock in a transaction dated Friday, May 17th. The shares were acquired at an average cost of $4.00 per share, with a total value of $18,000.00. Following the acquisition, the executive vice president now directly owns 17,889 shares of the company’s stock, valued at $71,556. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ ADMA opened at $4.34 on Wednesday. ADMA Biologics Inc has a 12 month low of $2.08 and a 12 month high of $6.96. The company has a debt-to-equity ratio of 5.70, a quick ratio of 2.39 and a current ratio of 4.60. The stock has a market capitalization of $190.96 million, a price-to-earnings ratio of -2.99 and a beta of 3.05.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.06). ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%. The company had revenue of $4.06 million during the quarter, compared to analyst estimates of $5.19 million. As a group, analysts predict that ADMA Biologics Inc will post -1.24 EPS for the current fiscal year.



Several research analysts have recently weighed in on ADMA shares. Oppenheimer boosted their price target on shares of ADMA Biologics from $14.00 to $16.00 and gave the company an “outperform” rating in a research report on Tuesday, April 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of ADMA Biologics in a research report on Thursday, February 7th. Maxim Group set a $12.00 target price on shares of ADMA Biologics and gave the company a “buy” rating in a research report on Thursday, February 14th. WBB Securities raised shares of ADMA Biologics to a “buy” rating in a research report on Thursday, April 4th. Finally, ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Nine equities research analysts have rated the stock with a buy rating, ADMA Biologics presently has a consensus rating of “Buy” and a consensus price target of $11.42.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth about $177,000. Morgens Waterfall Vintiadis & Co. Inc. lifted its position in shares of ADMA Biologics by 43.8% during the first quarter. Morgens Waterfall Vintiadis & Co. Inc. now owns 575,000 shares of the biotechnology company’s stock worth $2,179,000 after purchasing an additional 175,000 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of ADMA Biologics during the first quarter worth about $853,000. ExodusPoint Capital Management LP acquired a new stake in shares of ADMA Biologics during the first quarter worth about $59,000. Finally, Northern Trust Corp lifted its position in shares of ADMA Biologics by 11.1% during the first quarter. Northern Trust Corp now owns 261,571 shares of the biotechnology company’s stock worth $991,000 after purchasing an additional 26,066 shares in the last quarter. 53.19% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://dakotafinancialnews.com/2019/05/22/james-mond-acquires-4500-shares-of-adma-biologics-inc-adma-stock.html.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Further Reading: Gap Down Stocks

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.